The United Kingdom and the United States have announced a major commercial pact that will guarantee zero tariffs on British drug products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This commitment ensures that duties on these crucial exports will stay at zero for a period of the next three years.
This agreement is in response to previous statements to significantly raise duties on branded pharmaceutical imports, with potential rates mentioned reaching 100%.
"This agreement between the UK bolsters the global environment for innovative medicines and establishes long-overdue equity to transatlantic pharmaceutical trade," an announcement noted.
Trade Significance
Pharmaceuticals constitute one of the the United Kingdom's biggest goods shipped to the United States, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to last September, the UK exported drugs worth over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This guarantee protects work, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Specific NHS Changes
The agreement includes several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments exceeded 20%.
Broader Context
The pact follows a ongoing dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
These tensions were intensified by arguments that US customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the previous ten-year period.
